Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Grows By 188.7%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 146,372 shares, a growth of 188.7% from the January 29th total of 50,692 shares. Approximately 1.9% of the company’s shares are short sold. Based on an average daily volume of 124,954 shares, the short-interest ratio is currently 1.2 days. Based on an average daily volume of 124,954 shares, the short-interest ratio is currently 1.2 days. Approximately 1.9% of the company’s shares are short sold.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Stock Performance

NASDAQ:ANEB opened at $0.36 on Friday. Anebulo Pharmaceuticals has a fifty-two week low of $0.35 and a fifty-two week high of $3.42. The firm has a market cap of $14.68 million, a PE ratio of -1.89 and a beta of -0.81. The business has a 50 day moving average price of $0.88 and a 200-day moving average price of $1.89.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings results on Friday, February 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Research analysts predict that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.